Jounce's shares hit after release of efficacy data from trial of ICOS agonist JTX-2011

Shares in Jounce Therapeutics fell nearly as much as 28 percent after the company released an overview of efficacy data to be presented at the American Society of Clinical Oncology (ASCO) annual meeting from a study investigating its ICOS agonist JTX-2011 in patients with gastric cancer and triple negative breast cancer (TNBC).

Results from the Phase I/II ICONIC trial, with a cut-off date of January 27, showed that in patients given JTX-2011 alone, one out of seven patients with gastric cancer had a partial response, while no subjects with TNBC had a response. Meanwhile, in patients given JTX-2011 in combination with Bristol-Myers Squibb's Opdivo (nivolumab), two out of 19 subjects with gastric cancer had a partial response, while there was one partial response in 15 patients with TNBC.

Jounce noted that updated results, including preliminary efficacy data on all evaluable patients in the trial, will be presented at the ASCO conference from a cut-off date of April 4. Elizabeth Trehu, Jounce's chief medical officer, added that "a potential surrogate biomarker of response has been identified that may help to guide JTX-2011 development."

In 2016, Jounce entered a deal potentially worth as much as $2.6 billion with Celgene, giving the latter options on JTX-2011 and up to four early-stage programmes. For related analysis, see ViewPoints: With so-so combo data, Jounce becomes the first ASCO fatality.

To read more Top Story articles, click here.